↓ Skip to main content

Regulatory Aspects of Gene Therapy and Cell Therapy Products

Overview of attention for book
Attention for Chapter 8: Regulatory Frameworks for Gene and Cell Therapies in Japan
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
policy
2 policy sources
twitter
2 X users

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Regulatory Frameworks for Gene and Cell Therapies in Japan
Chapter number 8
Book title
Regulatory Aspects of Gene Therapy and Cell Therapy Products
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-3-319-18618-4_8
Pubmed ID
Book ISBNs
978-3-31-918617-7, 978-3-31-918618-4
Authors

Daisuke Maeda, Teruhide Yamaguchi, Takami Ishizuka, Masakazu Hirata, Kazuhiro Takekita, Daisaku Sato, Maeda, Daisuke, Yamaguchi, Teruhide, Ishizuka, Takami, Hirata, Masakazu, Takekita, Kazuhiro, Sato, Daisaku

Abstract

The regulations for the human use of advanced therapy medical products such as gene and cell therapy products have evolved in accordance with advance of clinical experience, scientific knowledge, and social acceptance to these technologies. In Japan, two laws, the Pharmaceuticals and Medical Devices (PMD) Act and the Act on the Safety of Regenerative Medicine (ASRM), were enacted in November 2014. The PMD Act defines regenerative medical products for the first time and introduces a system for the conditional and time-limited marketing authorization of regenerative medical products. Under ASRM, the responsibilities of medical institutions to ensure the safety and provide transparency of such medical technologies are described. Amendments to accompanying guidelines for these two Acts are currently in preparation. It is expected that the new legislative frameworks will promote the timely development of new products and technologies, to bring safe and effective regenerative medicines to Japanese patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 25%
Student > Doctoral Student 4 14%
Student > Master 4 14%
Student > Bachelor 1 4%
Researcher 1 4%
Other 1 4%
Unknown 10 36%
Readers by discipline Count As %
Medicine and Dentistry 4 14%
Pharmacology, Toxicology and Pharmaceutical Science 3 11%
Agricultural and Biological Sciences 3 11%
Biochemistry, Genetics and Molecular Biology 2 7%
Social Sciences 2 7%
Other 4 14%
Unknown 10 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2024.
All research outputs
#2,263,004
of 25,550,333 outputs
Outputs from Advances in experimental medicine and biology
#335
of 5,263 outputs
Outputs of similar age
#30,049
of 360,433 outputs
Outputs of similar age from Advances in experimental medicine and biology
#20
of 272 outputs
Altmetric has tracked 25,550,333 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,263 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,433 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.